Table 1.
Characteristics of Patients and Administered T cells
| Synovial cell sarcoma | Melanoma | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||||
| Patient | Age/ Sex |
Sites of Disease |
Prior Treatments |
Cells (×109) |
IL-2 doses |
CDS+/ CD4+(% of CD3+) |
Tetramer+ CDS+/CD4+ (% of CD3+) |
Patient | Age/ Sex |
Sites of Disease |
Prior Treatments |
Cells (×109) |
IL-2 doses |
CDS+/ CD4+(% of CD3+) |
Tetramer+ CDS+/CD4+ (% of CD3+) |
| 1 | 20/M | lu,bo | S,R,I,C(2)* | 83 | 5 | 82/8 | 63/5 | 19 | 52/M | ln | S,R,I | 130 | 6 | 97/2 | 83/1 |
| 2 | 37/F | lu | S,R,C(4) | 50 | 8 | 90/5 | 70/4 | 20 | 60/F | sc,lu | S,I | 71 | 6 | 82/17 | 62/9 |
| 3 | 47/F | lu, ln | S,R,C(2) | 56 | 8 | 89/11 | 72/8 | 21 | 30/F | bo,ln,panc,sb | S,R,I | 47 | 1 | 98/1 | 78/1 |
| 4 | 19/M | lu | S,R,C(1) | 16 | 5 | 46/40 | 31/25 | 22 | 56/M | lu,ki | S,R,I | 50 | 7 | 91/9 | 73/7 |
| 5 | 30/M | pl, hi | S,C(2) | 59 | 5 | 92/8 | 68/5 | 23 | 32/M | ln | S,I,C | 64 | 4 | 98/2 | 83/2 |
| 6 | 40/M | pl, hi | S,R,C(3) | 52 | 5 | 81/18 | 63/12 | 24 | 38/M | ln | S,I | 51 | 7 | 93/7 | 81/6 |
| 7 | 64/F | bo, lu | S,R,C(5) | 39 | 5 | 83/17 | 72/13 | 25 | 47/M | ln,lu | S,R,I | 23 | 7 | 96/4 | 67/2 |
| 8 | 37/M | lu | S,C(2) | 22 | 6 | 87/13 | 66/4 | 26 | 39/F | ln, br,lu | S,R,I,C | 38 | 8 | 68/32 | 53/22 |
| 9 | 21/F | lu | S,R,C(1) | 77 | 1 | 89/11 | 56/6 | 27 | 51/F | lu, ln,li | S,I,C | 31 | 10 | 94/6 | 78/4 |
| 10 | 31/F | lu | S,C(2) | 30 | 5 | 93/7 | 33/2 | 28 | 61/M | ln,li,spl,lu,bo | S,R,I,C | 16 | 8 | 84/16 | 66/9 |
| 11 | 65/F | lu | S,R,C(2) | 63 | 4 | 73/27 | 40/20 | 29 | 46/M | lu, li | S,R,I | 37 | 6 | 93/7 | 59/4 |
| 12 | 40/M | pane, bo | S,C(3) | 120 | 1 | −‡ | − | 30 | 39/M | lu, bo,li | S,R,I | 9 | 7 | 82/15 | 59/9 |
| 13 | 24/M | sc, lu | S,C(1) | 30 | 0 | 89/11 | 56/5 | 31 | 61/F | ln | S,I | 36 | 3 | 70/29 | 51/19 |
| 14 | 43/F | sc, pl | S,C(1) | 55 | 5 | 90/10 | 67/6 | 32 | 39/M | ln | S,I,C | 36 | 7 | 88/12 | 78/8 |
| 15 | 27/M | lu | S,C(1) | 69 | 4 | 83/17 | 52/11 | 33 | 51/M | ln, c | S,I | 49 | 6 | 89/11 | 70/7 |
| 16 | 40/M | lu | S,I,C(6) | 83 | 1 | 74/26 | 44/18 | 34 | 30/M | lu | S,I | 50 | 5 | 94/5 | 74/4 |
| 17 | 47/F | lu | S,C(2) | 33 | 4 | 45/55 | 33/39 | 35 | 55/M | ki,pl | S | 57 | 0 | 74/26 | 61/19 |
| 18 | 46/M | lu | S,C(1) | 57 | 7 | 62/38 | 52/31 | 36 | 65/M | lu, ln, ki | S,R,I | 55 | 3 | 93/7 | 76/6 |
| 37 | 64/M | ln, sp | S,I | 82 | 5 | 57/43 | 44/41 | ||||||||
| 38 | 51/M | ln | S,I,C | 78 | 4 | 92/8 | 74/7 | ||||||||
Abbreviations used: ln, lymph node; sc,subcutaneous; lu,lung; bo, bone; panc,pancreas; sb,small bowel; ki,kidney; br,brain; spl,spleen; pl,pleura; hi,hilum; S, Surgery; R, Radiation; I, Immunotherapy; C,Chemotherapy.
*
The number of chemotherapy regimens administered to synovial cell sarcoma patients prior to adoptive transfer is noted in parentheses.
‡
The T cells administered to Patient 12, who developed sepsis and died three days following adoptive transfer, were not further characterized.